Grow Taller 4 Idiots

How to Grow Taller

Get Instant Access

1. Wright AD, Hill DM, Lowery C, et al. mortality in acromegaly. Quart J Med 1970;39:1-16.

2. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980;12:71-79.

3. Ritchie CM, Atkinson AB, Kennedy AL, et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 1990;59:55-62.

4. Etxabe J, Gaztambide S, Latorre P, et al. Acromegaly: An epidemiologic study. J Endocrinol Invest 1993;16:181-187.

5. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102.

6. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730-2734.

7. Bates AS, Van't Hoff, W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Quart J Med 1993;86:293-299.

8. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 2000;85:526-529.

9. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas. Clin Endocrinol 1998;45:517-522.

10. Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-3426.

11. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89:353-358.

12. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. J Clin Endocrinol Metab 1998;83:3411-3418.

13. Kreutzer J, Vance ML, Lopes MBS, Laws ER. Surgical management of growth hormone secreting pituitary adenomas. An outcome study using modern remission criteria. J Clin Endocrinol Metab 2001;86:4072-4077.

14. Barkan AL. Acromegaly: diagnosis and therapy. Endocrinol Metab Clin North Am 1989;18:277-310.

15. Quabbe HJ, Plockinger U Dose-response study and long-term effects of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab 1989;68:873-881.

16. McKnight JA, McCance DR, Sheridan B, et al. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly. Clin Endocrinol 1991;34:119-125

17. Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly—effects of dose and frequency and long-term safety. Ann Inter Med 1990;112:173-181.

18. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 1991;151:1573-1578.

19. Ezzat S, Snyder PJ, Yourn WF, et al. Octreotide treatment of acromegaly: a randomized multicenter trial. Ann Intern Med 1992;117:711-718.

20. Newman CB, Melmed S, Snyder PJ et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients. J Clin Endocrinol Metab 1995;80:2768-2775.

21. Lucas-Morante T, Garcia-Urda J, Estada J, et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 1994;81:10-14.

22. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-3272.

23. Flogstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997;82:23-28.

24. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue Lanreotide. Eur J Endocrinol 1994;131:20-26.

25. Giusti M, Gussoni G, Cuttica CM, Giordano G, and the Italian Multicenter Slow Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian Multicenter Study. J Clin Endocrinol Metab 1996;81:2089-2097

26. Al-Maskari M, Gebbie J, Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol 1996;45:415-421.

27. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.

28. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177.

29. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759.

30. Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 1979;48:931-940.

31. Levy RP, Fabrikant JI, Frankel KA. Particle-beam irradiation of the pituitary gland. E Alexander, JS Woffler, CD Lunsford, eds. In: Stereotactic Radiosurgery. 1993;157-165.

32. Thoren M, Rahn T, Gou WY, Werner S. Stereotactic radiosurgery with the cobalt-60 gamma unit in the treatment of growth hormone-producing pituitary tumors. Neurosurgery 1991;29:663-668.

33. Laws ER, Vance ML. Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin North Am 1999;10:327-336.

34. Vance ML. Medical progress: hypopituitarism. New Engl J Med 1994;330:1651-1662.

35. Synder PJ, Fowble BF, Shatz NJ. Hypopituitarism following radiation therapy for pituitary adenomas. Am J Med 1986;81:457-462.

Was this article helpful?

0 0

Post a comment